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Combined Effect of Inflammatory Gene Polymorphisms
and the Risk of Ischemic Stroke in a Prospective Cohort
of Subjects With Type 2 Diabetes: A Go-DARTS Study
Colin N.A. Palmer,1 Charlotte H. Kimber,1 Alex S.F. Doney,2 Anna S. Proia,3 Andrew D. Morris,2
Eleonora Gaetani,3 Miriam Quarta,3 Roy C. Smith,4 and Roberto Pola3,4
OBJECTIVE—We have previously observed that genetic pro-
files determined by the combination of five functionally signifi-
cant single nucleotide polymorphisms (SNPs) (rs1800795,
rs5498, rs5361, rs1024611, and rs679620) of genes encoding
prototypical inflammatory molecules are associated with history
of ischemic stroke. Here we tested the ability of this multigenic
model to predict stroke risk in a large population-based prospec-
tive cohort of subjects with type 2 diabetes.
RESEARCH DESIGN AND METHODS—This study was con-
ducted using a prospective cohort of individuals with type 2
diabetes participating in the Go-DARTS (Genetics of Diabetes
Audit and Research in Tayside Scotland) study, which includes
genetic and clinical information of patients with diabetes within
the Tayside region of Scotland, U.K. The above-mentioned in-
flammatory SNPs were investigated in 2,182 Go-DARTS partici-
pants. We created an inflammatory risk score (IRS), ranging from
0 to 5, according to the number of “at-risk” genotypes concomi-
tantly carried by a given individual. The primary outcome was the
occurrence of fatal or nonfatal stroke of any kind. Mean fol-
low-up time was 6.2  1.1 years.
RESULTS—The incidence of stroke increased according to the
IRS. The IRS was significantly and independently associated with
increased stroke risk after adjustment for other conventional risk
factors (hazard ratio 1.34 [95% CI 1.1–1.7]; P  0.009). The
highest hazard ratio for stroke was found in subjects concomi-
tantly carrying 3 proinflammatory variations and in subjects
without previous cardiovascular diseases.
CONCLUSIONS—This large prospective cohort study provides
evidence that SNPs of genes encoding prototypical inflammatory
molecules may be used to create multigenic models that predict
stroke risk in subjects with type 2 diabetes. Diabetes 59:
2945–2948, 2010
Proinflammatory single nucleotide polymorphisms(SNPs) may contribute to the development andprogression of pathological conditions, includingcardiovascular diseases (1–7). Inflammatory gene
variations may act synergistically, determining genetic
profiles associated with increased risk for disease (8–13).
We have previously demonstrated that genetic profiles
determined by the combination of SNPs of five prototypi-
cal inflammatory genes are associated with history of
ischemic stroke. In particular, we have found that the
combined analysis of the rs1800795, rs5498, rs5361,
rs1024611, and rs679620 of the interleukin-6 (IL-6),
monocyte chemoattractant protein-1 (MCP-1), intercellu-
lar adhesion molecule-1 (ICAM-1), selectin-E (sel-E), and
matrix metalloproteinase-3 (MMP-3) genes may be used to
create genetic profiles that are associated with different
odds of stroke in a case-control scenario (10). A similar
combination of inflammatory SNPs is also associated with
peripheral artery disease (PAD) and critical limb ischemia
(CLI) (11).
Here, we investigated whether this multigenic model
may predict stroke risk in a large population-based pro-
spective cohort of subjects with type 2 diabetes. We
studied 2,182 diabetic individuals participating in the pro-
spective Go-DARTS (Genetics of Diabetes Audit and Re-
search in Tayside Scotland) study and found that risk for
stroke is significantly and independently influenced by an
inflammatory risk score (IRS) determined by the combi-
nation of the five SNPs mentioned above.
RESEARCH DESIGN AND METHODS
We studied 2,182 individuals with type 2 diabetes in the Go-DARTS study.
Additional information on Go-DARTS is available in the online appendix
available at http://diabetes.diabetesjournals.org/cgi/content/full/db09-1690/
DC1. The study was approved by the local research ethics committee.
Genetic analyses and creation of the multigenic model. The following
SNPs were analyzed: IL-6 174G/C rs1800795, MCP 2518A/G rs1024611,
ICAM-1 469E/K rs5498, sel-E Ser128Arg rs5361, and MMP-3 117155A/6A
rs679620. According to our previous study (10), the following genotypes were
considered “at risk”: IL-6 GG and GC, MCP-1 GG, ICAM-1 EE, sel-E RR
(ArgArg), and MMP-3 5A5A. The IRS model was created as a continuous
variable, ranging from 0 to 5, based on the number of “at-risk” genotypes
concomitantly carried by a given individual. The population was stratified
prior to evaluation of the number of disease events and execution of the
statistical analyses. Additional information is available in the online appendix.
Disease events. All individuals were followed up until their first nonfatal or
fatal stroke after recruitment. Nonfatal strokes were determined from both
the hospital Scottish Morbidity Record and the DARTS program of nurse-
facilitated validation. Fatal events were determined from death certificates
obtained from the General Register Office for Scotland, as previously de-
scribed (14–16). Additional information is available in the online appendix.
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Statistical analyses. Cox regression was used to determine the association
of genotype with stroke after recruitment. Survival functions were adjusted
for age at recruitment and sex. For smoking, a composite variable was
constructed (ever-smokers genotype, ever-smokers genotype, never-
smokers genotype, and never-smokers genotype) and entered as indicator
variables. Fully adjusted models, which included ratio of total-to-HDL choles-
terol, mean arterial pressure, and years with diabetes, were also considered.
STATA version 8 was used for all analyses. Additional information is available
in the online appendix.
RESULTS
The demographic and clinical characteristics of the study
population are presented in Table 1. The cohort consisted
of 1,147 male and 1,035 female subjects (mean age 64.5 
11.7 years). Mean age at diagnosis was 56.8  12.2 years.
Mean duration of diabetes was 7.7  6.5 years. A total of
1,109 subjects were “ever-smokers” (50.8%), 720 subjects
had previous cardiovascular diseases (myocardial infarc-
tion and/or stroke) (33.0%), and 200 subjects had previous
history of stroke (9.2%). During the follow-up period
(6.2  1.1 years), the overall incidence of new fatal and
nonfatal strokes was 4.9% (108 events).
Genotype and allele frequencies of the individual vari-
ants in the study cohort are shown in supplemental Table
1. Allele frequencies of all variants were in Hardy-Wein-
berg equilibrium. The association of individual variants
with prospective risk for stroke is shown in Table 2. In this
analysis, we also considered whether the association
between individual gene variations and stroke risk was
influenced by smoking. None of the investigated gene
variants increased the risk for stroke when considered
alone. The ICAM-1 EE genotype demonstrated a signifi-
cant association with stroke in smokers (hazard ratio [HR]
2.6 [95% CI 1.2–6.0]; P  0.02).
The distribution of subjects according to the IRS is
shown in supplemental Fig. 1. No subjects with an IRS of
5 were identified in our cohort. The occurrence of isch-
emic stroke over the follow-up period increased according
to the IRS, with an incidence of 1.0, 4.5, 4.7, 6.4, and 10.9%
among subjects with IRS 0, 1, 2, 3, and 4, respectively
(supplemental Fig. 2). Cox proportional hazards analyses
were performed to assess the relative risk for stroke
according to the IRS. These analyses were performed on a
total of 2,123 individuals for whom full covariates were
available. In this subset of subjects, the incidence of stroke
(4.8%, 104 events) did not differ from that observed in the
overall study cohort (n  2,182, incidence of stroke 4.9%,
108 events). After correcting for age, smoking habit, blood
pressure, cholesterol ratio, and presence of previous car-
diovascular diseases, the IRS was significantly and inde-
pendently associated with increased stroke risk (HR 1.34
per risk allele [95% CI 1.1–1.7]; P  0.009) (Table 3). The
effect of IRS was mainly seen in individuals free of
cardiovascular diseases at entry (supplemental Table 2).
The percentage of subjects that survive without stroke
differs according to the IRS, with individuals who have an
IRS of 4 showing the lowest stroke-free survival (Fig. 1).
DISCUSSION
Multigenic approaches have been demonstrated to be valid
tools for identifying subjects at risk for complex traits,
such as type 2 diabetes (17) and coronary artery disease
(18). A similar strategy was used in the present study,
hypothesizing that, in subjects with type 2 diabetes, an
TABLE 1
Characteristics of the study cohort
Total sample size 2,182
Female subjects 1,035 (47.4%)
Male subjects 1,147 (52.6%)
Age (years) 64.5 11.7
BMI (kg/m2) 30.2 5.45
Duration of diabetes (years) 7.7 6.5
Age at diagnosis (years) 56.8 12.2
Smoker (ever) 1,109 (50.8%)
Previous cardiovascular disease 720 (33.0%)
Previous stroke 200 (9.2%)
Follow-up (years) 6.2 11
Strokes (fatal and nonfatal) after enrollment 108 (4.9%)
Data are means  SD or n (%).
TABLE 2
Association of individual increased risk variants with prospective
risk of stroke
Variant Model HR (95% CI)* P
IL-6 GG/GC genotype 1.2 (0.6–1.9) 0.626
Smoking (ever) 0.9 (0.4–4.3) 0.683
MCP-1 GG genotype 1.4 (0.9–2.0) 0.102
Smoking (ever) 1.0 (0.4–2.1) 0.857
ICAM-1 EE genotype 1.2 (0.8–2.0) 0.365
Smoking (ever) 2.6 (1.2–6.0) 0.022
sel-E RR genotype 2.0 (0.5–8.0) 0.346
Smoking (ever) NA** NA
MMP3 5A5A genotype 1.5 (1.0–2.2) 0.075
Smoking (ever) 1.6 (0.7–3.7) 0.273
*All models adjusted for age at study recruitment and sex. **Zero
individuals in at least one cell. NA, not available.
TABLE 3
IRS genotypic model and risk of stroke in the Go-DARTS study
HR (95% CI) P
IRS 1.34 (1.1–1.7) 0.009
Age at enrollment 1.06 (1.0–1.1) 0.001
Smoking (ever) 1.52 (1.0–2.3) 0.038
Previous cardiovascular disease 2.10 (1.4–3.1) 0.001
Mean arterial pressure 1.02 (0.8–1.1) 0.087
Cholesterol ratio 3.93 (0.8–18.7) 0.085
Analyses were performed on 2,123 genotyped individuals with full
covariates available for Cox proportional hazards study. Number of
incident strokes is 104.
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FIG. 1. Kaplan-Meier plot of stroke-free survival among the Go-DARTS
population stratified by IRS.
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increasing number of proinflammatory alleles may confer
a significant risk of developing ischemic stroke. We have
previously demonstrated the utility of the Go-DARTS
cohort to study the contribution of gene variations to
cardiovascular risk in subjects with diabetes (14–16). To
our knowledge, this is the first prospective study that
attempts to look at the impact of the combined effect of
multiple gene variations on incident stroke. It is also the
first prospective study considering the combination of
multiple inflammatory SNPs in diabetic individuals.
The decision to study the rs1800795, rs5498, rs5361,
rs1024611, and rs679620 of the IL-6, MCP-1, ICAM-1,
sel-E, and MMP-3 genes was based on the following
criteria. First, all five SNPs are functionally important. The
rs1800795 is a SNP of the IL-6 promoter and influences
the transcription rate of the gene and IL-6 plasma concen-
tration (2). Similarly, the rs1024611 is a SNP of the
promoter and affects the expression rate of the MCP-1
gene (1,4). Also the rs679620 of the MMP-3 gene is a SNP
promoter and regulates transcription and protein levels in
an allele-specific manner (5). Regarding the rs5498 of the
ICAM-1 gene and the rs5361 of the sel-E gene, these SNPs
lead to changes in the amino acid sequence of the corre-
sponding proteins that result in modifications of their
biological activity. In particular, the rs5498 of the ICAM-1
gene affects the Ig-like domain 5 of the ICAM-1 protein,
which is crucial for the interactions with lymphocyte
function-associated antige-1 (LFA-1) and the adhesion of
B-cells (6). On the other hand, the rs5361 of the sel-E gene
alters the ability of the E-sel protein to regulate leukocyte-
endothelial interactions (3). Previous reports have impli-
cated these SNPs in the pathobiology of atherosclerosis
and stroke (6,19). We have previously reported that these
SNPs are significantly and independently associated with
history of ischemic stroke in a case-control scenario (10).
Finally, we have shown that a combination of SNPs similar
to that investigated in this study is associated with PAD
and CLI (11). It should be noted that the synergistic and
interdependent effects of these SNPs are mirrored by some
important physiological interactions displayed by the cor-
responding proteins. For instance, MCP-1 is able to stim-
ulate IL-6 secretion, and ICAM-1 synthesis is stimulated by
MCP-1 in a time- and dose-dependent manner (20,21). On
the other hand, ICAM-1 induces expression of several
proinflammatory cytokines, including IL-6, which in turn
induces the synthesis of various acute-phase proteins, thus
maintaining and promoting the inflammatory phenotype
(21,22). Taken together, these data indicate that the SNPs
investigated in this study create a proinflammatory state
that facilitates the development of atherosclerotic and
ischemic disorders, such as stroke.
In a recent prospective study, the rs1800795 of the IL-6
gene has been associated with fasting glucose levels and
development of diabetes (23). This raises the possibility
that at least some of the SNPs composing our IRS affect
the severity of diabetes. According to this hypothesis,
increased risk of stroke might depend on subjects with
high IRS having more severe diabetes. However, this
hypothesis cannot be tested in the Go-DARTS study,
because parameters of diabetes severity are not available.
The analysis of our multigenic model in prospective co-
horts in which outcomes of diabetes severity are available
might address this issue.
None of the SNPs evaluated in our study have been
associated with stroke in recent genome-wide association
studies (GWASs) (24–27). Although this might appear
disappointing, it is not inconsistent with our findings, if
one considers that, in our study also, none of the five
investigated SNPs was significantly and independently
associated with incidence of stroke when considered
alone. It was the combinatorial analysis of these five SNPs
that provided evidence of their association with increased
stroke risk, and no GWASs have so far investigated the
possibility that this or similar proinflammatory multigenic
models are associated with stroke or other cardiovascular
diseases. In this respect, it will be interesting to test our
multigenic model in existing GWAS databases, in order to
understand whether individuals carrying multiple proin-
flammatory SNPs are more common in the groups of
subjects with stroke than in control groups. This would
also indicate that GWASs should take into consideration
the fact that SNPs that fall below the threshold of statis-
tical significance when considered alone might instead be
associated with a disease when evaluated in combination.
This concept suggests that future studies should use
genome-wide data to evaluate specific types of functional
associations within biologically relevant pathways, thus
combining the unbiased approach of GWASs with the
hypothesis-driven approach of candidate gene studies.
Further studies are also needed to understand if the
addition of multigenic models to conventional risk factors
improves measures of calibration, discrimination, and risk
reclassification for cardiovascular events. We have per-
formed a receiver operating characteristic analysis to
compare the predictive value of our multigenic profile with
the conventional risk profile for stroke and observed only
a small increase (1.1%) in predictive value (supplemental
Fig. 3). However, our current model is based on a limited
number of functional gene variations centered around an
inflammatory hypothesis, and it is highly unlikely that we
have exhausted all the possible genetic contributory fac-
tors. In its current state, the IRS model represents a work
in progress that may improve as additional alleles are
added, but the model is, as currently formulated, predic-
tive of future risk of stroke in subjects with type 2
diabetes. Further validation will be necessary, and its
predictive ability in the general population and for addi-
tional cardiovascular indications remains to be tested, but
this study suggests a viable strategy for developing genetic
profiles at risk.
This study has some potential limitations. First, our
results need to be replicated in additional cohorts. Second,
we did not perform an analysis of the different subtypes of
ischemic stroke. Therefore, it is possible that our multi-
genic model predicts the risk only of some stroke sub-
types. Finally, we cannot exclude that the observed
associations depend on the effect of genes in linkage
disequilibrium with those investigated in our study.
In conclusion, we demonstrate that variations of genes
encoding prototypical inflammatory molecules synergisti-
cally interact to determine proinflammatory genetic pro-
files that significantly influence the risk of stroke in
subjects with type 2 diabetes. This multigenic model of
stroke risk merits further investigation as a new, potential,
independent predictor of individual risk for cardiovascular
diseases.
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